X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Infection and Drug Resistance

期刊標題檢索 INFECT DRUG RES 最新評論: Hello, from September 24th to October 15th, it has been 2D - First ... (2024-10-14)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Infection and Drug Resistance]您好,您是該頁面的第 57759 位訪客。

期刊簡介
期刊名稱Infection and Drug Resistance Infection and Drug Resistance
LetPub Score
6.5
50 ratings
Rate

Reputation
7.2

Influence
5.3

Speed
9.0

期刊簡稱INFECT DRUG RESIST
ISSN1178-6973
h-index27
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.600.7430.947
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q288 / 272
Category: Medicine
Subcategory: Infectious Diseases
Q2126 / 344
Category: Medicine
Subcategory: Pharmacology
Q2134 / 313

自引率 (2023-2024)6.90%自引率趨勢
掲載範囲
About Journal
Editors
Peer Reviewers
Articles

Article Publishing Charges
Aims and Scope
Call For Papers

ISSN: 1178-6973

Editor-in-Chief: Professor Suresh Antony

An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
官方網站https://www.dovepress.com/infection-and-drug-resistance-journal
在線稿件提交https://www.dovepress.com/submit_step_1.php
開放訪問Yes
出版商Dove Medical Press Ltd.
主題領域Medicine
出版國/地區UNITED STATES
發行頻率
創刊年0
每年文章數682每年文章數趨勢
黃金OA百分比98.64%
OA Related Info
APC: Yes( USD3300; )
APC waiver:Check Notes
Other charges: No
Keywords: bacterial infection、viral infection、fungal infection、antibiotic resistance、anti-infective drugs、infection control
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
INFECTIOUS DISEASESSCIEQ258/132
PHARMACOLOGY & PHARMACYSCIEQ2147/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-6973%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 16 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Infection and Drug Resistance】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    npj Breast CancerH-index: 0

    CiteScore: 10.10
    ACS Pharmacology & Translational ScienceH-index: 0

    CiteScore: 10.00
    Therapeutic Advances in Drug SafetyH-index: 0

    CiteScore: 6.70
    Translational and Clinical PharmacologyH-index: 0

    CiteScore: 1.60
    Medizinische Monatsschrift fur PharmazeutenH-index: 0

    CiteScore: 0.10
    Adverse Drug Reaction BulletinH-index: 0

    CiteScore: 0.70
    WHO Drug InformationH-index: 0

    CiteScore: 0.20
    Cancer and Chemotherapy ReviewsH-index: 0

    CiteScore: 0.10
    Journal fur Pharmakologie und TherapieH-index: 0

    CiteScore: 0.10
    P and TH-index: 0

    CiteScore: 7.60
    學科內最受檢索的期刊 頁面查看次數
    npj Breast Cancer15257
    ACS Pharmacology & Translational Science9853
    Therapeutic Advances in Drug Safety6625
    OpenNano3184
    Medicine in Drug Discovery2917
    WHO Drug Information2243
    P and T1854
    Cancer and Chemotherapy Reviews1648
    Journal fur Pharmakologie und Therapie1606
    Medizinische Monatsschrift fur Pharmazeuten1586
  •  

    Infection and Drug Resistance Infection and Drug Resistance
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)
  [Infection and Drug Resistance] 的評論撰寫評論
作者: 晨风峻成


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-14 15:47:52 評論於
Hello, from September 24th to October 15th, it has been 2D - First Report Returned continuously. Do you suggest writing a reminder letter?
(0) 讚! | 晨风峻成

作者: 晨风峻成


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-14 09:24:07 評論於
I have been in 2D (First Report Returned) status for 20 days and the status hasn't changed yet, still waiting.
(0) 讚! | 晨风峻成

作者:


領域:
審稿時間: 0.0 month(s)
結果:


撰寫評論

2024-10-13 10:17:59 評論於
 (0) 讚! |   

作者: 忆28


領域: 医学
審稿時間: 4.0 month(s)
結果: 拒稿


撰寫評論

2024-08-07 00:43:38 評論於
It took a long time to gather three reviewers. Submitted on 4.3, passed compliance check on 6.18, selected reviewers on 6.26, returned to the editor-in-chief on 8.2, and rejected on 8.6.
(0) 讚! | 忆28

作者: xuxuxuxu333


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2024-07-24 22:32:58 評論於
The review process, acceptance, and publication are all very fast, and it is very friendly to Chinese scholars. The only downside is that the publication fee is expensive. It is very suitable for publishing case studies.
(0) 讚! | xuxuxuxu333

作者: 埃利斯佩蒂


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-07 15:45:02 評論於
Waited for a month, changed from 1A1 to 1A2, received an email saying I have to wait another month.
(0) 讚! | 埃利斯佩蒂

作者: 辉夜玄穆


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-03 13:20:34 評論於
Generally speaking, it takes 15-20 days to be published, but if you are in a hurry, you can communicate with the editor.
(0) 讚! | 辉夜玄穆

作者: Murphy Dobbin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-03 11:27:53 評論於
Hello, can I ask how long it usually takes from submitting the layout fee for this magazine to publication? Thank you.
(0) 讚! | Murphy Dobbin

作者: 五郎兴怀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-02 23:50:04 評論於
It's like this, how are you now? I am just getting ready to submit for external review.
(0) 讚! | 五郎兴怀

作者: 南风跃华


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-02 21:22:28 評論於
I invested in 4-30, and my status has not changed so far. I want to withdraw now.
(0) 讚! | 南风跃华

作者: 墟散云泽


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-30 11:05:40 評論於
Research focus: Clinical experience sharing: Submitted on May 27th, the system shows 1A without receiving any reminder emails. However, the system has sent two emails stating that they have a large number of submissions recently and hope for patience from authors. Is this the case for everyone?
(0) 讚! | 墟散云泽

作者: 太山德本


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-13 17:12:49 評論於
Will the revision be reviewed externally?
(0) 讚! | 太山德本

作者: 太山德本


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-27 15:54:29 評論於
Is the revision rejected?
(0) 讚! | 太山德本

作者: Marsh Blake


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-19 09:06:13 評論於
Hello, how is your initial review going? It's been almost a month for me and I'm still in the initial review process
(0) 讚! | Marsh Blake

作者: 太山德本


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-08 16:56:37 評論於
Do you have a display for 2GX?
(0) 讚! | 太山德本

作者: 太山德本


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-08 10:05:49 評論於
Review speed: 4.0 | Submission hit rate: 50.0 Emphasized research direction: bioinformatics Sharing experience: Does 2GX represent a rejection?
(0) 讚! | 太山德本

作者: 江南谷菱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-02 16:03:59 評論於
It has been over a month for me
(0) 讚! | 江南谷菱

作者: 狒狒1


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-21 16:49:00 評論於
Do we need to edit this journal?
(0) 讚! | 狒狒1

作者: 巴蜀语柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-04 22:51:58 評論於
What does submission status 1AB mean?
(0) 讚! | 巴蜀语柔

作者: 犬走鸿轩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-29 22:46:22 評論於
Is it still normal to be in the initial review after two weeks?
(0) 讚! | 犬走鸿轩

作者: 豆花❀


領域: 医学
審稿時間: 2.0 month(s)
結果: 拒稿


撰寫評論

2024-02-12 14:23:35 評論於
Submitted on November 20, 2023. Notice sent on January 31, 2024 for incomplete reviewers
(0) 讚! | 豆花❀

作者: 无极志行


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-13 12:49:32 評論於
How long does the external audit take?
(0) 讚! | 无极志行

作者: 东海浩旷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-02 18:40:15 評論於
How long did it take to find the reviewers?
(0) 讚! | 东海浩旷

作者: 振英mm


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-29 21:44:17 評論於
Review speed: 3.0 | Submission hit rate: 50.0
Experience sharing: Acceptance after two rounds of revisions, taking about 3 months from submission
(0) 讚! | 振英mm

作者: 悦人少女


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-28 20:36:41 評論於
Review speed: 3.0 | Submission hit rate: 50.0 Emphasis on research direction: bioinformatics sharing experience: Was rejected after 3 months, found two reviewers, one gave good feedback, the other seemed to be a clinician. I used a machine learning model to predict a certain disease, the performance was very good, but he immediately said it was meaningless because clinical diagnosis should be based on imaging results. Without imaging, the selected indicators definitely cannot predict, etc. Really frustrated, if everything is included, doctors will diagnose it, there is significance in me doing this model...... Not understanding and not respecting. It's not an article within their own field, at least hope they can be quiet
(0) 讚! | 悦人少女

首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)

開始撰寫 [Infection and Drug Resistance] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*